UCB general manager Selina Clifford said, "As our understanding of the genetic mutations underlying Dravet syndrome continues to grow, we remain focused on developing innovative solutions to address the unique challenges of this complex neurological condition." …
UCB welcomes the PBS listing of dual-acting anti-seizure medication
May 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy
May 5, 2025 - - Australian Biotech -
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 - - Australian Biotech -
FDA grants fast track designation for Alterity's ATH434 to treat multiple aystem atrophy
May 5, 2025 - - Australian Biotech -
New immune therapy treatment option for women diagnosed with advanced endometrial cancer
May 4, 2025 - - Latest News -
Stakeholders should hope for continuity in the health portfolio
May 4, 2025 - - Latest News -
UCB welcomes the PBS listing of dual-acting anti-seizure medication
May 4, 2025 - - Latest News -
Pharma, pharmacy and biotech congratulate Government for re-election
May 4, 2025 - - Latest News